{"filing":{"accession_number":"0001703057-26-000053","cik":"0001703057","ticker":"ABCL","company_name":"AbCellera Biologics Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"abcl-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/abcl-20260810.htm"},"events":[{"id":26377,"run_id":23968,"accession_number":"0001703057-26-000053","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"AbCellera announced positive Phase 2 clinical trial results for ABCL635, demonstrating statistically significant reductions in vasomotor symptoms frequency and severity with a favorable safety profile. This is a material clinical milestone for a clinical-stage biotech company's lead program, but it does not fit the \"earnings_release\" category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant product development milestone—making \"operational_other\" the most appropriate classification.","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27473,"accession_number":"0001703057-26-000053","item_number":"7.01","item_title":"Regulation FD","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"AbCellera announced positive Phase 2 clinical trial results for ABCL635, demonstrating statistically significant reductions in vasomotor symptoms frequency and severity with a favorable safety profile. This is a material clinical milestone for a clinical-stage biotech company's lead program, but it does not fit the \"earnings_release\" category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant product development milestone—making \"operational_other\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:50:40.944607+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27473,"accession_number":"0001703057-26-000053","item_number":"7.01","item_title":"Regulation FD","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"AbCellera announced positive Phase 2 clinical trial results for ABCL635, demonstrating statistically significant reductions in vasomotor symptoms frequency and severity with a favorable safety profile. This is a material clinical milestone for a clinical-stage biotech company's lead program, but it does not fit the \"earnings_release\" category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant product development milestone—making \"operational_other\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:50:40.944607+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-08-10"}]}